[1]
Belkaid, Y.; Harrison, O.J. Homeostatic Immunity and the Microbiota. Immunity, 2017, 46(4), 562-576.
[2]
Pagliari, D.; Gambassi, G.; Piccirillo, C.A.; Cianci, R. The Intricate Link among Gut “Immunological Niche,” Microbiota, and Xenobiotics in Intestinal Pathology. Mediators of inflammation, 2017, 2017, 8390595.
[3]
Ansaldo, E.; Farley, T.K.; Belkaid, Y. Control of Immunity by the Microbiota. Annual review of immunology, 2021, 39, 449-479.
[4]
Piccioni, A.; Cicchinelli, S.; Valletta, F.; De Luca, G.; Longhitano, Y.; Candelli, M.; Ojetti, V.; Sardeo, F.; Navarra, S.; Covino, M.; Franceschi, F. Gut Microbiota and Autoimmune Diseases: a Charming Real World Together with Probiotics. Curr. Med. Chem., 2022, 29(18), 3147-3159.
[5]
Cassini, C.; Zatti, P.H.; Angeli, V.W.; Branco, C.S.; Salvador, M. Mutual effects of free and nanoencapsulated phenolic compounds on human microbiota. Curr. Med. Chem., 2022, 29(18), 3160-3178.
[6]
Zanza, C.; Romenskaya, T.; Thangathurai, D.; Ojetti, V.; Saviano, A.; Abenavoli, L.; Robba, C.; Cammarota, G.; Franceschi, F.; Piccioni, A.; Longhitano, Y. Microbiome in critical care: An unconventional and unknown ally. Curr. Med. Chem., 2022, 29(18), 3179-3188.
[7]
Cianci, R.; Franza, L.; Massaro, M.G.; Borriello, R.; Tota, A.; Pallozzi, M.; De Vito, F.; Gambassi, G. The Crosstalk between Gut Microbiota, Intestinal Immunological Niche and Visceral Adipose Tissue as a New Model for the Pathogenesis of Metabolic and Inflammatory Diseases: The Paradigm of Type 2 Diabetes Mellitus. Curr. Med. Chem., 2022, 29(18), 3189-3201.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
11
1